Le Lézard

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences, Inc.  today announced the presentation of new data from a clinician survey highlighting the functional impact experienced by patients with mild tardive dyskinesia (TD) severity ...

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

New analysis from the IMPACT-TD Registry confirms tardive dyskinesia (TD) causes a significant burden for most individuals with concomitant mood ...

Teva Pharmaceutical Industries Ltd: Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite ...

New analysis from the IMPACT-TD Registry confirms tardive dyskinesia (TD) causes a significant burden for most individuals with concomitant mood disorders, impacting their lives regardless of ageThe d ...

Neurocrine Biosciences, Inc.: Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

Strengthens Neurocrine's rare disease portfolio with VYKAT XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched ...
HDBuzz

Prilenia’s Application for European Approval of Pridopidine Withdrawn

Regular HDBuzz readers may recall our September 2024 article examining the long history of pridopidine in Huntington’s ...